Table 3. Distribution of the GCKR rs780094 and rs1260326 polymorphisms in the study groupsa,b.
Genotype | Controls | NAFLD | NAFLD + CAD | OR (95%CI) | χ2 | p1 | OR (95%CI) | χ2 | p2 | OR(95%CI) | χ2 | p3 |
rs780094 | ||||||||||||
CC | 26 (17.1%) | 26 (18.3%) | 18 (22.0%) | |||||||||
CT + TT | 126 (82.9%) | 116 (81.7%) | 64 (78.0%) | 0.837 (0.455–1.538) | 0.073 | 0.787 | 0.734 (0.375–1.473) | 0.819 | 0.365 | 1.255 (0.640–2.642) | 0.437 | 0.509 |
Alleles | ||||||||||||
C | 133 (43.8%) | 123 (43.3%) | 75 (45.7%) | |||||||||
T | 171 (56.2%) | 161 (56.7%) | 89 (54.3%) | 0.982 (0.709–1.361) | 0.012 | 0.914 | 1.083 (0.740–1.587) | 0.169 | 0.681 | 1.103 (0.749–1.624) | 0.247 | 0.619 |
rs1260326 | ||||||||||||
CC | 23 (15.1%) | 24 (16.9%) | 15 (18.3%) | |||||||||
CT + TT | 129 (84.9%) | 118 (83.1%) | 67 (81.7%) | 0.877 (0.470–1.636) | 0.171 | 0.679 | 1.256 (0.615–2.565) | 0.351 | 0.532 | 0.908 (0.446–1.850) | 0.07 | 0.791 |
Alleles | ||||||||||||
C | 128 (42.1%) | 121 (42.6%) | 71 (43.3%) | |||||||||
T | 176 (57.9%) | 163 (57.4%) | 93 (56.7%) | 1.021 (0.736–1.416) | 0.015 | 0.902 | 1.050 (0.715–1.541) | 0.061 | 0.804 | 1.028 (0.698–1.516) | 0.02 | 0.887 |
Abbreviations: NAFLD, patients with nonalcoholic fatty liver disease; NAFLD + CAD, patients with nonalcoholic fatty liver disease and coronary artery disease.
Data were compared by chi-square test.
Values are expressed as n (%).